Stimulatory capacity of mDCs electroporated with gag mRNA versus DCs pulsed with HxB-2 Gag peptide pool
Patients or controls . | mDC-mock . | mDC-hHxB-2 gag . | mDC-pv-gag . | mDC-v-gag . | mDC-pulsed HxB-2 Gag . |
|---|---|---|---|---|---|
| IFN-γ SFCs per 106 PBMCs | |||||
| P16 | 6 ± 1 | 64 ± 18 | — | — | 742 ± 56 |
| P17 | 68 ± 26 | 482 ± 70 | — | — | 722 ± 56 |
| P19 | 67 ± 32 | 118 ± 62 | — | — | 740 ± 0 |
| GM ± SE | 30 ± 21 | 154 ± 31 | — | — | 735 ± 6 |
| P15 | 4 ± 8 | — | 58 ± 5 | 252 ± 54 | 774 ± 60 |
| P20 | 30 ± 16 | — | 620 ± 331 | 327 ± 79 | 2369 ± 81 |
| P21 | 94 ± 112 | — | 771 ± 101 | 219 ± 40 | 572 ± 240 |
| P22 | 78 ± 18 | — | 116 ± 38 | 98 ± 44 | 574 ± 120 |
| GM ± SE | 31 ± 21 | — | 238 ± 179 | 205 ± 48 | 881 ± 435 |
| IFN-γ SFCs per 106 CD4+ T cells | |||||
| P16 | 50 ± 10 | 156 ± 11 | — | — | 1154 ± 2 |
| P17 | 46 ± 4 | 56 ± 8 | — | — | 424 ± 64 |
| P19 | 30 ± 10 | 26 ± 4 | — | — | 186 ± 36 |
| GM ± SE | 41 ± 6 | 61 ± 39 | — | — | 450 ± 292 |
| P15 | 306 ± 26 | — | 158 ± 10 | 686 ± 18 | 1782 ± 224 |
| P20 | 48 ± 0 | — | 536 ± 0 | 328 ± 3 | 2642 ± 0 |
| P21 | 58 ± 0 | — | 280 ± 3 | 224 ± 4 | 672 ± 2 |
| P22 | 36 ± 14 | — | 160 ± 48 | 128 ± 12 | 356 ± 32 |
| GM ± SE | 74 ± 65 | — | 248 ± 89 | 283 ± 122 | 1030 ± 525 |
| IFN-γ SFCs per 106 CD8+ T cells | |||||
| P16 | 41 ± 4 | 253 ± 4 | — | — | 441 ± 15 |
| P17 | 120 ± 10 | 1210 ± 22 | — | — | 490 ± 270 |
| P19 | 26 ± 17 | 112 ± 4 | — | — | 720 ± 9 |
| GM ± SE | 50 ± 29 | 325 ± 345 | — | — | 538 ± 86 |
| P15 | 204 ± 66 | — | 662 ± 36 | 908 ± 72 | 1536 ± 28 |
| P20 | 40 ± 4 | — | 1018 ± 32 | 604 ± 34 | 2554 ± 36 |
| P21 | 133 ± 0 | — | 1307 ± 3 | 1107 ± 4 | 1251 ± 2 |
| P22 | 130 ± 26 | — | 576 ± 104 | 604 ± 16 | 1428 ± 32 |
| GM ± SE | 109 ± 34 | — | 844 ± 169 | 778 ± 123 | 1627 ± 293 |
| IFN-γ SFCs per 106 PBMCs | |||||
| C4 | 11 ± 4 | 17 ± 2 | — | — | 248 ± 13 |
| C5 | 22 ± 5 | 46 ± 8 | — | — | 291 ± 37 |
Patients or controls . | mDC-mock . | mDC-hHxB-2 gag . | mDC-pv-gag . | mDC-v-gag . | mDC-pulsed HxB-2 Gag . |
|---|---|---|---|---|---|
| IFN-γ SFCs per 106 PBMCs | |||||
| P16 | 6 ± 1 | 64 ± 18 | — | — | 742 ± 56 |
| P17 | 68 ± 26 | 482 ± 70 | — | — | 722 ± 56 |
| P19 | 67 ± 32 | 118 ± 62 | — | — | 740 ± 0 |
| GM ± SE | 30 ± 21 | 154 ± 31 | — | — | 735 ± 6 |
| P15 | 4 ± 8 | — | 58 ± 5 | 252 ± 54 | 774 ± 60 |
| P20 | 30 ± 16 | — | 620 ± 331 | 327 ± 79 | 2369 ± 81 |
| P21 | 94 ± 112 | — | 771 ± 101 | 219 ± 40 | 572 ± 240 |
| P22 | 78 ± 18 | — | 116 ± 38 | 98 ± 44 | 574 ± 120 |
| GM ± SE | 31 ± 21 | — | 238 ± 179 | 205 ± 48 | 881 ± 435 |
| IFN-γ SFCs per 106 CD4+ T cells | |||||
| P16 | 50 ± 10 | 156 ± 11 | — | — | 1154 ± 2 |
| P17 | 46 ± 4 | 56 ± 8 | — | — | 424 ± 64 |
| P19 | 30 ± 10 | 26 ± 4 | — | — | 186 ± 36 |
| GM ± SE | 41 ± 6 | 61 ± 39 | — | — | 450 ± 292 |
| P15 | 306 ± 26 | — | 158 ± 10 | 686 ± 18 | 1782 ± 224 |
| P20 | 48 ± 0 | — | 536 ± 0 | 328 ± 3 | 2642 ± 0 |
| P21 | 58 ± 0 | — | 280 ± 3 | 224 ± 4 | 672 ± 2 |
| P22 | 36 ± 14 | — | 160 ± 48 | 128 ± 12 | 356 ± 32 |
| GM ± SE | 74 ± 65 | — | 248 ± 89 | 283 ± 122 | 1030 ± 525 |
| IFN-γ SFCs per 106 CD8+ T cells | |||||
| P16 | 41 ± 4 | 253 ± 4 | — | — | 441 ± 15 |
| P17 | 120 ± 10 | 1210 ± 22 | — | — | 490 ± 270 |
| P19 | 26 ± 17 | 112 ± 4 | — | — | 720 ± 9 |
| GM ± SE | 50 ± 29 | 325 ± 345 | — | — | 538 ± 86 |
| P15 | 204 ± 66 | — | 662 ± 36 | 908 ± 72 | 1536 ± 28 |
| P20 | 40 ± 4 | — | 1018 ± 32 | 604 ± 34 | 2554 ± 36 |
| P21 | 133 ± 0 | — | 1307 ± 3 | 1107 ± 4 | 1251 ± 2 |
| P22 | 130 ± 26 | — | 576 ± 104 | 604 ± 16 | 1428 ± 32 |
| GM ± SE | 109 ± 34 | — | 844 ± 169 | 778 ± 123 | 1627 ± 293 |
| IFN-γ SFCs per 106 PBMCs | |||||
| C4 | 11 ± 4 | 17 ± 2 | — | — | 248 ± 13 |
| C5 | 22 ± 5 | 46 ± 8 | — | — | 291 ± 37 |
Immature DCs were pulsed with HxB-2 Gag peptide pool (mDC-pulsed HxB-2 Gag) or electroporated with codon-optimized gag (mDC-hHxB-2 Gag, autologous proviral (mDC-pv-gag), or viral (mDC-v-gag) gag mRNA or mock electroporated (mDC-mock). After maturation, these cells were cocultured with autologous PBMCs, purified CD4+ cells, or CD8+ T cells in ELISPOT plates. The amounts of IFN-γ SFCs per 106 responder cells (triplicate wells) are shown as GM ± SE. GM ± SE was calculated from the data of 2 groups of HIV-1—seropositive patients, where different comparisons were made: patients P16, P17, and P19 on one hand and patients P15, P20, P21, and P22 on the other hand.
Controls (C4 and C5) were HIV-1—seronegative individuals.
— indicates not done.